Specific immunotherapy (xenovaccinotherapy) for cancer

Melanoma

Malignant melanoma is a cancer with one of the most rapidly increasing incidence rates. Surgical resection of the early-stage localized disease is the only curative treatment. Metastatic melanoma is usually resistant to the standard cytotoxic therapy, including highly toxic combinations. Hence, immunotherapy has become the mainstay of treatment in advanced melanoma. An active specific immunotherapy (vaccination) is a strategy using tumor-associated antigens (TAAs) for inducing an antitumor immune process... read more

Kidney cancer

Although curative treatments for kidney cancer involve removing the local (primary) tumor, cancer that has spread beyond the kidney requires treatment of all areas of the body (systemic therapy). Consequently, a lot of attention is now focused on a relatively new approach to treatment of kidney cancer called immunotherapy. The goal of immunotherapy is to boost the body's immune system to more effectively fight off or destroy cancer cells... read more

Colorectal cancer

Colorectal carcinoma is one of the most common cancers. Surgical resection of early-stage localized disease is the only curative treatment. Advanced colon cancer is usually resistant to standard cytotoxic therapy including chemotherapy and radiotherapy. On the other hand, evidence is accumulated that immune-based approaches may materially affect course of that disease... read more

Gastric cancer

Gastric cancer is one of the most common cancers. Surgical resection of early-stage localized disease is the only curative treatment. Advanced gastric cancer is usually resistant to standard cytotoxic therapy including chemotherapy and radiotherapy. On the other hand, evidence is accumulated that immune-based approaches may materially affect course of this disease... read more

Lung cancer

More than one in four of all diagnosed cancers involve the lung, and lung cancer remains the most common cancer-related cause of death among men and women... read more

Prostate cancer

The systemic treatment of patients with metastatic proatate cancer is mainly based on hormonotherapy that is directed to inhibiting testosterone production and action in the body. However, irrespective of used treatment regime, all patients ultimately become unresponsivive to hormonotherapy. This typically occurs at 12-to-18 months after therapy initiation. The median survival in the patients with hormone-independent prostate cancer is within the limits of 6–to-8 months. The standard treatment of such patients is usually palliative and directed to support the quality of their life. Consequently, a lot of attention is now focused on a relatively new approach to treatment of prostate cancer called immunotherapy. The goal of immunotherapy is to boost the body's immune system to more effectively fight off or destroy cancer cells... read more

Astrocytoma

Therapeutic vaccination is a strategy that uses tumor-associated antigens (TAAs) to induce an tumor-specific immune process. The xenogenic (murine) polyantigenic vaccine (XPV) -in which there are main families of common tumor associated antigens (TAA)- has been developed in the Institute of Clinical immunology (a patent RF № 2192884). Xenovaccinotherapy has significant advantages over the vaccinal approaches based on applying homologous (autological or allogeneic) tumor cells or their antigenic derivates... read more

back to the top